Stock HBIO HARVARD BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Harvard Bioscience, Inc.

Equities

HBIO

US4169061052

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
3.26 USD -0.61% Intraday chart for Harvard Bioscience, Inc. +19.85% -39.07%
Jul. 01 Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell Small Cap Comp Value Index CI
Jul. 01 Harvard Bioscience, Inc.(NasdaqGM:HBIO) added to Russell 3000E Value Index CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Harvard Bioscience Unit Named as Exclusive Distributor of Etisense's Cardiorespiratory Monitoring Product
MT
Insider Buy: Harvard Bioscience
MT
Harvard Bioscience CFO Michael Rossi Resigns, Jennifer Cote Named Interim CFO; Shares Drop 5%
MT
Harvard Bioscience, Inc. Announces Executive Changes
CI
Insider Buy: Harvard Bioscience
MT
Insider Buy: Harvard Bioscience
MT
Harvard Bioscience, Inc. Announces Executive Changes
CI
Insider Trends: 90-Days of Insider Buying at Harvard Bioscience Eased Back with Share Disposition
MT
Harvard Bioscience, Inc. Announces Executive Changes
CI
Harvard Bioscience Announces Appointment of Susan Steele to Board of Directors
CI
Harvard Bioscience, Inc. Appoints Yash Singh as Executive Vice President, Cellular & Molecular Technologies
CI
Harvard Bioscience, Inc. Appoints Ken Olson as Vice President and General Manager, Pre-Clinical Systems
CI
Harvard Bioscience, Inc. Names Alan Edrick to the Board of Directors
CI
Harvard Bioscience, Inc. Announces Management Changes
CI
Harvard Bioscience, Inc. Announces Management Changes
CI
Harvard Bioscience, Inc. Announces Resignation of Yong Sun as Vice President and General Manager of Physiology, Cell and Molecular Instruments, Effective as of January 4, 2019
CI
Harvard Bioscience, Inc. Hires Seth Hertel as New Vice President and General Manager
CI
Harvard Bioscience, Inc. Appoints Kamalam Unninayar as Chief Financial Officer, Effective November 26, 2018
CI
Harvard Bioscience, Inc. Announces the Resignation of Robert E. Gagnon, Chief Financial Officer, Effective August 31, 2018
CI
Harvard Bioscience, Inc. Appoints Katherine Eade and Thomas Loewald as Class II Directors of the Board of Directors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HBIO Stock
  4. News Harvard Bioscience, Inc.
  5. Insiders